Solventum Corporation research snapshot
SOLV AI stock analysis reads Solventum Corporation as a healthcare spinoff with durable clinical franchises, improving adjusted earnings, and a balance sheet that still needs free cash flow to prove out. At the August 2, 2026 cutoff, SOLV closed at $85.44 on July 31, 2026, with a market cap near $14.8 billion. Q1 2026 sales were $2.007 billion with organic growth of 2.1%, adjusted EPS rose 10.6% to $1.48, and management affirmed 2026 guidance with adjusted EPS expected toward the high end of the $6.40 to $6.60 range. The stock forecast is scenario-based, not a fixed price promise: the base case is roughly flat because the stock now trades above the mean analyst target, upside needs cash flow conversion and margin execution, and downside risk comes from weak free cash flow, transition costs, leverage, and a failed move below support.
Current price
$85.44
Market cap
$14.80 billion calculated from 173.17 million shares
AI score
68 / 100
Rating
Improved momentum, but the re-rating has reduced the margin of safety
Trend status
Positive but extended: price is above rising moving averages near the top of the 52-week range, with daily momentum signals showing overbought conditions
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Solventum sells medical surgical, dental, health information, and filtration-related healthcare products that sit inside repeat clinical workflows, hospital purchasing, and healthcare data software rather than discretionary consumer demand. | Medium-high |
| Moat | The moat comes from installed clinical habits, regulatory approvals, brand equity such as Littmann and wound care franchises, quality systems, global distribution, and switching friction in hospitals, dental practices, and health information systems. | Medium-high |
| Management | CEO Bryan Hanson has deep medtech operating experience, and Q1 2026 execution beat expectations. The test now is cash generation, portfolio discipline, and responding to Trian Fund Management pressure on cost structure and divestitures without losing focus. | Medium |
| Financial trend | Q1 2026 reported sales fell 3.0% to $2.007 billion while organic sales grew 2.1%; adjusted EPS rose 10.6% to $1.48, but free cash flow was negative $273 million and operating cash flow was negative $189 million. | High |
| Valuation | At $85.44, SOLV trades near 12.9x the high end of the 2026 adjusted EPS guidance range and about 11.8x forward earnings, but the stock is above the mean analyst target of about $83.91 and the free cash flow yield is low against the roughly $200 million 2026 FCF guide. | Medium-high |
| Technical trend | ChartMill showed a 9/10 technical rating, price at $85.44 above rising 20-day, 50-day, and 200-day moving averages, support near $78.60, resistance near $86.14, but overbought daily and weekly stochastics with a weak 3/10 setup rating. | Medium |
| Risk level | Main risks are spinoff execution, leverage, transition costs, tariffs and inflation, reimbursement pressure, weak cash conversion, the activist campaign, product quality issues, and organic growth falling below guidance with Q2 2026 earnings due August 5, 2026. | Medium-high |
| AI confidence | AI confidence is high for sourced financial facts and medium for forecasts because 2025 and trailing net income include major divestiture effects and standalone history is short. | High data confidence |
| Investment certainty | SOLV can work if the company converts healthcare brands into steady cash flow and reduces debt, but the stock has re-rated above consensus targets, so investors need to wait for proof that adjusted earnings convert into sustainable free cash flow. | Medium |
SOLV AI stock forecast
The SOLV AI stock forecast uses a scenario range built around the $85.44 price reference, the 2026 adjusted EPS guidance high end near $6.60, and a three-year earnings multiple framework. The audited model produced a bearish value near $65, a base value near $90, and a bullish value near $121. Because SOLV already trades above the mean analyst target of about $83.91, the base case offers only modest upside from the current price.
$110 to $128
More likely if organic sales hold near 2% to 3%, adjusted operating margin expands toward the 20% long-range plan, free cash flow rises well above the $200 million 2026 guide after transition payments fade, debt falls, and the market awards a mid-teens earnings multiple. Q2 2026 results on August 5, 2026 are the first confirmation point.
$82 to $98
More likely if SOLV grows low single digits organically, adjusted EPS tracks near the high end of the $6.40 to $6.60 range, cash conversion improves gradually, and investors hold the valuation near 12x to 13x forward adjusted earnings. This case is close to the mean analyst target and the current price.
$58 to $72
More likely if free cash flow remains weak, reported sales keep shrinking, transition costs and tariffs persist, reimbursement pressure erodes margins, the activist campaign distracts management, or the market compresses the multiple toward 10x while waiting for proof.
SOLV AI technical analysis
SOLV AI technical analysis is positive but extended as of the August 2, 2026 cutoff. ChartMill showed a July 31, 2026 close of $85.44, a 9/10 technical rating, price above the rising 20-day ($79.77), 50-day ($78.37), and 200-day ($75.26) moving averages, support near $78.60, and resistance near $86.14. Daily and weekly indicator consensus was Strong Buy, but daily RSI near 62.6, daily stochastics near 86.9, and a 3/10 setup rating mean the stock is extended near the upper end of its 52-week range and needs consolidation or a clean breakout to justify adding exposure.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $85.44 | ChartMill and StockAnalysis listed this SOLV close for July 31, 2026, down 1.59% on the day. |
| Immediate support | $78.60 | ChartMill cited this support area. A support zone between roughly $77.94 and $79.77 combines trend lines and moving averages across multiple time frames. |
| Near resistance | $86.14 | ChartMill cited this resistance from a weekly time frame horizontal line. A close above it would open a test of the $88.65 52-week high. |
| Moving averages | 20-day near $79.77, 50-day near $78.37, 100-day near $73.28, 200-day near $75.26 | ChartMill listed these SMAs. Price is above all of them, with the shorter averages rising. |
| Momentum | RSI (14) near 62.6, MACD near 0.87, daily stochastics near 86.9 | ChartMill showed neutral RSI and a positive but declining MACD, while stochastics are overbought on both daily and weekly time frames. |
| Volume | Average volume near 1.64 million shares | ChartMill cited this average. A breakout above $86.14 is more credible if volume expands above this average. |
| Volatility | Medium daily risk | ChartMill listed ATR around 2.9% of price, which is medium volatility for a healthcare supply stock. |
| Invalidation | Close below $78 | A close below the $77.94 to $79.77 support zone would weaken the positive setup and shift attention back to free cash flow and debt risk. |
SOLV AI trading strategy
The SOLV AI trading strategy below is a rules-based research framework, not personal advice. It links the technical setup with Q2 2026 results on August 5, 2026, free cash flow conversion, debt reduction, and healthcare equipment peer action.
Watch for SOLV to close above $86.14 and hold that level on follow-through volume toward the $88.65 52-week high. Confirmation should include stable 2026 guidance after the August 5 earnings report, adjusted EPS tracking toward the high end, and no new warning on transition costs or free cash flow.
A failed breakout that falls back below $78 should reduce setup confidence because it would show the overhead resistance still controls the chart and the stock is extended after a strong run.
If SOLV pulls back toward the $78.60 to $79.77 support zone without a guidance cut, compare the move with Medtronic, Boston Scientific, Danaher, and health care supplies peers, then check whether free cash flow weakness is seasonal or structural and how the Trian campaign evolves.
Do not treat weakness as a normal pullback if reported sales decline accelerates, margin guidance falls, free cash flow stays negative into the second half, or debt reduction stalls.
Track Q2 2026 sales, organic growth, adjusted operating margin, adjusted EPS, operating cash flow, free cash flow, net debt, tariff commentary, transition agreement exit payments, SKU exit effects, and any activist announcements from Trian Fund Management.
Position sizing should account for spinoff history, leverage, healthcare regulation, product liability, the activist overhang, and the gap between adjusted EPS and free cash flow.
Investment research summary
Solventum sells healthcare products and workflow tools that clinicians, hospitals, dental practices, and healthcare administrators use to deliver care, manage information, and improve patient outcomes. Customers pay for reliability, regulatory compliance, and productivity inside recurring clinical and data workflows.
The moat is based on clinical trust, regulatory approvals, installed product habits, brand equity such as Littmann, manufacturing quality, product breadth, and 3M-origin technical know-how. It is not invincible because hospitals can pressure price and competitors can attack individual categories.
The thesis fails if adjusted EPS is not converted into free cash flow, transition costs last longer than expected, healthcare customers delay purchases, tariffs or reimbursement pressure erode margins, the activist campaign distracts management, or debt limits reinvestment flexibility.
Bryan Hanson has relevant medtech leadership experience and Q1 2026 execution beat expectations. The key evidence to watch is cash generation, portfolio discipline, and how management balances the transformation plan with Trian Fund Management demands for cost cuts and divestitures.
The healthcare equipment, supplies, and health information market benefits from aging populations, procedural demand, care efficiency, and healthcare data and AI needs. The offset is regulation, payer pressure, hospital budget discipline, and product liability risk.
At about 12.9x the 2026 adjusted EPS guidance high end and about 11.8x forward earnings, SOLV is not priced like a high-growth medtech leader, but it now trades above the mean analyst target of about $83.91. The margin of safety depends on whether free cash flow normalizes after transition costs and debt falls from current levels.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $85.44 | ChartMill SOLV profile | August 2, 2026 |
| Market capitalization verification | $14.80 billion calculated from $85.44 x 173.17 million shares, matching the ChartMill reported $14.796 billion | Pineify financial_rigor.py market-cap check | August 2, 2026 |
| Q1 2026 sales | $2.007 billion, down 3.0% reported and up 2.1% organic | Solventum Q1 2026 earnings release | August 2, 2026 |
| Q1 2026 adjusted EPS | $1.48, up 10.6% year over year; GAAP diluted EPS $0.07 | Solventum Q1 2026 earnings release | August 2, 2026 |
| Q1 2026 free cash flow | Negative $273 million; operating cash flow negative $189 million | Solventum Q1 2026 earnings release | August 2, 2026 |
| FY2026 guidance | Organic sales growth 2.0% to 3.0%, adjusted EPS toward the high end of the $6.40 to $6.60 range, free cash flow about $200 million | Solventum Q1 2026 earnings release | August 2, 2026 |
| FY2025 revenue | $8.325 billion, cross-checked with Macrotrends and StockAnalysis | Solventum 2025 Form 10-K and Macrotrends | August 2, 2026 |
| FY2025 and trailing net income | FY2025 net income $1.556 billion includes the Purification and Filtration divestiture gain; trailing twelve month net income near $1.43 billion | Solventum 2025 Form 10-K and StockAnalysis | August 2, 2026 |
| Q1 2026 cash and total debt | $561 million cash and equivalents; $505 million short-term borrowings and $4.575 billion long-term debt | Solventum Q1 2026 Form 10-Q | August 2, 2026 |
| Shares outstanding | 173.17 million; 173,531,656 outstanding at March 31, 2026 | Solventum Q1 2026 Form 10-Q | August 2, 2026 |
| Technical support and resistance | Support $78.60, resistance $86.14 | ChartMill SOLV technical analysis | August 2, 2026 |
| Moving averages and momentum | 20-day SMA $79.77, 50-day SMA $78.37, 200-day SMA $75.26, RSI (14) 62.58, MACD 0.87, daily stochastics 86.93 | ChartMill SOLV technical analysis | August 2, 2026 |
| Analyst consensus reference | 22 analysts, buy consensus, mean price target $83.91, range $60.60 to $105.00 | ChartMill SOLV analyst ratings | August 2, 2026 |
| Next earnings date | Q2 2026 results scheduled August 5, 2026 | Solventum investor relations | August 2, 2026 |
This SOLV AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of August 2, 2026, and may be wrong if company results, market prices, rates, healthcare policy, activist activity, or investor sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
